<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599245</url>
  </required_header>
  <id_info>
    <org_study_id>MN39158</org_study_id>
    <secondary_id>2017-004886-29</secondary_id>
    <nct_id>NCT03599245</nct_id>
  </id_info>
  <brief_title>This is an Extension Study of the Roche P-trial to Investigate Safety and Effectiveness of a Single Ocrelizumab Dose in Participants With Multiple Sclerosis (MS)</brief_title>
  <official_title>A Single Arm, Open Label Multicentre Extension Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Multiple Sclerosis Previously Enrolled In A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple
      sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche)
      sponsored ocrelizumab phase IIIb/IV trial (i.e. the Parent, P-trial).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, open label, multicenter extension study in participants on ocrelizumab
      therapy at the end of Treatment period of the Roche P-trial. Participants will receive
      treatment with ocrelizumab as single 600 mg infusions every 24 weeks for two years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Anticipated">July 17, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of Ocrelizumab therapy in MS participants assessed by progression of disease</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>Participants have been enrolled in a Roche sponsored phase IIIb/IV-trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Time to onset of confirmed disability progression (CDP)</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>CDP is sustained for at least 24 weeks and for at least 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who have confirmed disability improvement (CDI) measured by expanded disability status scale (EDSS)</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>CDP for at least 24 weeks and for at least 48 weeks yearly and over the duration of the Extension study. The EDSS is performed by a neurologist. Stable EDSS is defined as EDSS change +/- 0.5. Worsening is &gt; 0.5 increase of EDSS, improvement is &gt; 0.5 decrease of EDSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who have confirmed disability progression measured by EDSS</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>The EDSS is performed by a neurologist. Stable EDSS is defined as EDSS change +/- 0.5. Worsening is &gt; 0.5 increase of EDSS, improvement is &gt; 0.5 decrease of EDSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who have improved, stable or worsened disability measured by expanded disability status scale (EDSS)</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>Disability of participants is compared with Baseline. Stable EDSS is define as EDSS change +/- 0.5. Worsening is &gt; 0.5 increase of EDSS, improvement is &gt; 0.5 decrease of EDSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in expanded disability status scale (EDSS) score</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>Disability of participants is compared with Baseline. Stable EDSS is define as EDSS change +/- 0.5. Worsening is &gt; 0.5 increase of EDSS, improvement is &gt; 0.5 decrease of EDSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 20% increase in timed 25-foot walk test (T25FWT) sustained for at least 24 weeks and for at least 48 weeks</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 20% increase in timed nine-hole peg test (9HPT) sustained for at least 24 weeks and for at least 48 weeks</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants achieving a sustained 20% increase in timed T25FWT</measure>
    <time_frame>Every 12 Months up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants achieving a sustained 20% increase in timed 9HPT</measure>
    <time_frame>Every 12 Months up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first protocol-defined event of disease activity</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first relapse</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualised relapse rate</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participant relapse free</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with no evidence of protocol-defined disease activity (NEDA)</measure>
    <time_frame>Every 12 Months up to 2 Years</time_frame>
    <description>Disease activity is defined as at least one the following events: protocol-defined relapse; 24 weeks CDP based on increases in EDSS; a T1 Gadolinium (Gd)-enhanced lesion; or a new and/or enlarging T2 hyperintense lesion on Magnetic Resonance Imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with no evidence of progression (NEP)</measure>
    <time_frame>Every 12 Months up to 2 Years</time_frame>
    <description>NEP is defined as no progression sustained for at least 24 weeks on all of the following three components: CDP; 20% increase in timed T25FWT; 20% increase in timed 9HPT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with no evidence of progression sustained for at least 24 weeks and no active disease (NEPAD)</measure>
    <time_frame>Every 12 Months up to 2 Years</time_frame>
    <description>NEPAD is defined as no progression on all of the three components of NEP (CDP, T25FWT, 9HPT), no new relapse and no enlarging or new T2 or T1 Gd-enhancing lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance as measured by the Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>From Baseline up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of T1 Gd-enhancing lesions as detected by brain MRI</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of new T2 lesion as detected by brain MRI</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of enlarging T2 lesion as detected by brain MRI</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total T1 hypointense lesion volume as detected by brain MRI</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of fluid-attenuated inversion-recovery (FLAIR) late enhancing lesions as detected by brain MRI</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in brain volume (including white and grey matter fractions) as detected by brain MRI</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and evolution of leptomeningeal follicles as detected by MRI</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment discontinuation</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment switch</measure>
    <time_frame>Up to 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Up to 6 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Change in locally reviewed MRI for safety (non-MS Central Nervous System (CNS) pathology)</measure>
    <time_frame>Up to 6 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Change in concomitant medication</measure>
    <time_frame>Up to 6 Years</time_frame>
    <description>Concomitant medications include pre-medications and medications used during and following ocrelizumab administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Ocrelizumab single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 600-mg infusion of Ocrelizumab every 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocrelizumab</intervention_name>
    <description>Participants will receive a single 600-mg infusion of Ocrelizumab. (In case of pregnancy, treatment will be interrupted, and the participant will be monitored for safety; however, the participant can be re-started with the treatment after the pregnancy and breastfeeding period.)</description>
    <arm_group_label>Ocrelizumab single-dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to comply with the study protocol, in the investigator's judgment.

          -  Completed the treatment period of Roche sponsored ocrelizumab P-trial (exception for
             female patients who were pregnant during MA30005 study and are still in the safety
             follow up period) and who in the opinion of the investigator may benefit from
             treatment with ocrelizumab and so are eligible for ocrelizumab re-treatment.

          -  Meet re-treatment criteria with ocrelizumab.

          -  For women of childbearing potential: agreement to use an acceptable birth control
             method during the treatment period and for at least 6 months after the last dose of
             study drug.

        Exclusion Criteria:

          -  Hypersensitivity to ocrelizumab or to any of its excipients.

          -  Participants in a severely immunocompromised state until the condition resolves.

          -  Evidence of any adverse event potentially attributable to ocrelizumab, for which the
             local label recommends permanent discontinuation.

          -  Existence of a contra-indication as per SmPC

          -  Participants who discontinued ocrelizumab, exemption made for treatment
             discontinuation because of pregnancy and breastfeeding and continued clinical study
             assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny; Neurologicka klinika</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava; NEU-Neurologicke oddeleni</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VFN Praha Poliklinika Rs Centrum - Budova A</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole; Neurologicka klinika 2. LF UK a FN Motol</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital, Neurologisk Afd. F, Skleroseklinikken</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Glostrup; Neurologisk Klinik</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital, Neurologisk Afdeling N; Neurologisk Ambulatorium N5; Skleroseklinikken</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydjysk Skleroseklinik - Sønderborg</name>
      <address>
        <city>Sønderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital; Neurology Department</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mehiläinen Neo Turku</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon Hopital Jean Minjoz; Service de Neurologie</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin; Service de neurochirurgie B</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro; Service de Neurologie</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone - Hopital d Adultes; Service de Neurologie</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gui de Chauliac; Neurologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Guillaume et René Laënnec; Service Neurologie</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur; Service de Neurologie</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié- Salpétrière; Service Neurologie</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hautepierre - CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincents University Hospital</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS. Annunziata - Clinica Neurologica - Centro Sclerosi Multipla</name>
      <address>
        <city>Chieti</city>
        <state>Abruzzo</state>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Salvatore; Clinica Neurologica - Centro Sclerosi Multipla</name>
      <address>
        <city>L'Aquila</city>
        <state>Abruzzo</state>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi della Campania Luigi Vanvitelli; Dip. Ass. Integrato Med Int-II Clinica Neur</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria; Istituto delle Scienze Neurologiche - UO RIABILITAZIONE SCLEROSI MULTIPLA</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Camillo Forlanini; UOSD Day Hospital Neurologico e Neurochirurgico</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli; UOC Neurologia - Centro Sclerosi Multipla</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Andrea; UOC Neurologia</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs A.O.U.San Martino Ist; Dinogmi</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Antonio Abate; Neurologia 2 - Sclerosi Multipla e Recupero Neurologico</name>
      <address>
        <city>Gallarate</city>
        <state>Lombardia</state>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico; UOSD Malattie Neurodegenerative</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Montichiari; Centro Sclerosi Multipla</name>
      <address>
        <city>Montichiari</city>
        <state>Lombardia</state>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Neurologico C. Mondino-Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi; SOD Clinica Neurologica-Am.Sclerosi Multipla</name>
      <address>
        <city>Ancona</city>
        <state>Marche</state>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla</name>
      <address>
        <city>Pozzilli</city>
        <state>Molise</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Casa Sollievo Della Sofferenza; SC Neurologia</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Puglia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Binaghi; Centro Sclerosi Multipla</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico V. Emanuele - P.O G. Rodolico; Clinica Neurologica, Centro Sclerosi Multipla</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Istituto S. Raffaele - Giglio; UO Neurologia</name>
      <address>
        <city>Cefalù</city>
        <state>Sicilia</state>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Giaccone; UOC Neurologia e Neurofisiopatologia-Amb Sclerosi Multipla</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Ospedali Riuniti Villa Sofia-Cervello;PO Villa Sofia - UO Neurologia - U.O.S. Neuroimmunologia</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Careggi; Neurologia 1-Dip. Neuroscienze Psicologia Area Farmaco Salute del Bambino(NEUROFARBA)</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOUC Azienda Ospedaliero-Universitaria Careggi; Neurologia 2</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Senese - Presidio Ospedaliero Le Scotte; UOSA Neurologia Sperimentale</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO di Perugia - Ospedale S. Maria della Misericordia; Clinica Neurologica</name>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova; Clinica Neurologica</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico G.B. Rossi; Dip. Scienze Neurologiche Biomediche - Neurologia B - Amb. Sclerosi Multipla</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstadziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum - Sittard Geleen</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-TweeSteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland universitetssykehus; Nevrologisk avdeling</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Buskerud HF; Nevrologisk avdeling</name>
      <address>
        <city>Drammen</city>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias; Servicio de Neurología</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge; Servicio de Neurologia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Castellon; Servicio de Neurología</name>
      <address>
        <city>Castelló de la Plana</city>
        <state>Castellon</state>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Neurologia</name>
      <address>
        <city>Salt</city>
        <state>Girona</state>
        <zip>17190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Neurologia</name>
      <address>
        <city>Coruña</city>
        <state>LA Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Neurología</name>
      <address>
        <city>Lleida</city>
        <state>Lerida</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron de Madrid; Servicio de Neurologia</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo - Xeral Cies; Servicio de Neurologia</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron; Servicio de Neurología</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar; Sevicio de Neurologia</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitario de La Princesa; Servicio de Neurología</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos; Servicio de Neurología</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz; Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Arrixaca; Servicio de Neurología</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena; Servicio de Neurologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia; Servicio de Neurologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe; Servicio de Neurologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Sjukhuset; Neurology</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum för Neurologi</name>
      <address>
        <city>Stockholm</city>
        <zip>113 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna; Neurology</name>
      <address>
        <city>Stockholm</city>
        <zip>113 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital (Wonford)</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <zip>IV2 3UV</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology and Neurosurgery,; MRC Centre for Neuromuscular Diseases</name>
      <address>
        <city>London</city>
        <zip>WC1 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospita</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morriston Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocrelizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

